Faster gene‑edited CAR T cell production for blood cancers
CORE C Technology Implementation/Development and Correlative Sciences
Making safer, faster gene‑edited CAR T cell treatments for people with relapsed or hard‑to‑treat blood cancers like AML and other lymphoid malignancies.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11192836 on NIH RePORTER |
What this research studies
At the University of Pennsylvania, two lab cores will work together to shorten and standardize how gene‑edited CAR T cells are made so treatments can be produced more quickly and consistently. They will use CRISPR and base‑editing methods to modify T cells (for example, removing CD5 or editing CD45) and will also edit matching blood stem cells when needed. The team will develop and run safety and product‑release tests that meet FDA expectations and support three linked clinical trials. These efforts are meant to improve manufacturing, safety testing, and the ability to move edited cell therapies into patient treatment.
Who could benefit from this research
Good fit: Adults with relapsed or refractory acute myeloid leukemia or relapsed lymphoid malignancies who meet eligibility for CAR T or gene‑edited cell therapy trials and can receive care at the trial site.
Not a fit: People without blood cancers, those who are medically ineligible for intensive cell therapies, or those who cannot travel to the trial center are unlikely to benefit directly from this grant's clinical activities.
Why it matters
Potential benefit: If successful, this could speed up access to personalized CAR T therapies and improve safety and durability for patients with AML and other resistant blood cancers.
How similar studies have performed: Standard CAR T therapies have shown clear benefit in some lymphoid cancers, but CRISPR/base‑edited CAR T approaches and CD45/CD5 edits remain experimental and are only beginning to be tested in patients.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Herbst-Nowrouzi, Friederike — University of Pennsylvania
- Study coordinator: Herbst-Nowrouzi, Friederike
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.